Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS)
CNY 10.72
(1.61%)
CNY 10.72
(1.61%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.69 Billion CNY | -11.85% |
| 2022 | 1.92 Billion CNY | 38.12% |
| 2021 | 1.39 Billion CNY | -16.5% |
| 2020 | 1.66 Billion CNY | 1163.13% |
| 2019 | 132.13 Million CNY | 226.01% |
| 2018 | -104.86 Million CNY | 73.63% |
| 2017 | -397.67 Million CNY | -257.92% |
| 2016 | 251.82 Million CNY | 137.64% |
| 2015 | -669.1 Million CNY | -464.32% |
| 2014 | 183.65 Million CNY | -57.31% |
| 2013 | 430.16 Million CNY | 9.45% |
| 2012 | 393.03 Million CNY | 38.21% |
| 2011 | 284.37 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 2.4 Billion CNY | -24.78% |
| 2024 Q1 | 1.92 Billion CNY | 13.3% |
| 2024 Q2 | 2.35 Billion CNY | 22.59% |
| 2023 Q3 | 2.26 Billion CNY | 2.36% |
| 2023 Q4 | 1.69 Billion CNY | -25.14% |
| 2023 FY | 1.69 Billion CNY | -11.85% |
| 2023 Q1 | 2.09 Billion CNY | 8.92% |
| 2023 Q2 | 2.21 Billion CNY | 5.62% |
| 2022 Q1 | 1.43 Billion CNY | 3.14% |
| 2022 FY | 1.92 Billion CNY | 38.12% |
| 2022 Q4 | 1.92 Billion CNY | 25.05% |
| 2022 Q3 | 1.53 Billion CNY | 6.19% |
| 2022 Q2 | 1.44 Billion CNY | 0.85% |
| 2021 FY | 1.39 Billion CNY | -16.5% |
| 2021 Q2 | 2.27 Billion CNY | 1.07% |
| 2021 Q1 | 2.24 Billion CNY | 34.77% |
| 2021 Q4 | 1.39 Billion CNY | -51.08% |
| 2021 Q3 | 2.84 Billion CNY | 25.3% |
| 2020 Q3 | 1.58 Billion CNY | 67.88% |
| 2020 Q2 | 946.43 Million CNY | 102.87% |
| 2020 Q1 | 466.51 Million CNY | 253.07% |
| 2020 FY | 1.66 Billion CNY | 1163.13% |
| 2020 Q4 | 1.66 Billion CNY | 5.04% |
| 2019 Q3 | 221.96 Million CNY | 132.95% |
| 2019 Q4 | 132.13 Million CNY | -40.47% |
| 2019 FY | 132.13 Million CNY | 226.01% |
| 2019 Q2 | 95.28 Million CNY | 1632.34% |
| 2019 Q1 | 5.5 Million CNY | 105.25% |
| 2018 Q2 | -114.59 Million CNY | 62.18% |
| 2018 Q3 | -105.52 Million CNY | 7.91% |
| 2018 FY | -104.86 Million CNY | 73.63% |
| 2018 Q4 | -104.86 Million CNY | 0.63% |
| 2018 Q1 | -302.97 Million CNY | 23.81% |
| 2017 Q2 | -165.99 Million CNY | 27.18% |
| 2017 FY | -397.67 Million CNY | -257.92% |
| 2017 Q4 | -397.67 Million CNY | -2062.75% |
| 2017 Q3 | 20.26 Million CNY | 112.21% |
| 2017 Q1 | -227.94 Million CNY | -190.52% |
| 2016 Q1 | -488.93 Million CNY | 26.93% |
| 2016 FY | 251.82 Million CNY | 137.64% |
| 2016 Q4 | 251.82 Million CNY | 459.12% |
| 2016 Q3 | -70.12 Million CNY | -30.33% |
| 2016 Q2 | -53.8 Million CNY | 89.0% |
| 2015 Q1 | 520.71 Million CNY | 183.53% |
| 2015 FY | -669.1 Million CNY | -464.32% |
| 2015 Q4 | -669.1 Million CNY | -15.1% |
| 2015 Q2 | -835.6 Million CNY | -260.47% |
| 2015 Q3 | -581.32 Million CNY | 30.43% |
| 2014 Q2 | 267.09 Million CNY | -57.93% |
| 2014 Q1 | 634.83 Million CNY | 0.0% |
| 2014 Q4 | 183.65 Million CNY | 0.0% |
| 2014 FY | 183.65 Million CNY | -57.31% |
| 2013 FY | 430.16 Million CNY | 9.45% |
| 2012 FY | 393.03 Million CNY | 38.21% |
| 2011 FY | 284.37 Million CNY | 0.0% |